Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 5
Submit an article Journal homepage
898
Views
23
CrossRef citations to date
0
Altmetric
Research Article

Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis

Franck E. NicoliniHôpital Edouard Herriot, Lyon, FranceCorrespondence[email protected]
,
Tamas MassziSt. István and St. László Hospital, Budapest, Hungary
,
Zhixiang ShenShanghai Ruijin Hospital, Shanghai, China
,
Neil J. GallagherNovartis Pharma AG, Basel, Switzerland
,
Saengsuree JootarRamathibodi Hospital, Mahidol University, Bangkok, Thailand
,
Bayard L. PowellWake Forest University School of Medicine, Winston-Salem, NC, USA
,
Pedro Enrique Dorlhiac-LlacerHospital das Clinicas FMUSP, São Paulo, Brazil
,
Ming ZhengNovartis Pharmaceuticals Corporation, Florham Park, NJ, USA
,
Tomasz SzczudloNovartis Pharmaceuticals Corporation, Florham Park, NJ, USA
&
Anna TurkinaHematology Research Center, Moscow, Russia
 show all
Pages 907-914 | Received 24 May 2011, Accepted 22 Sep 2011, Published online: 05 Dec 2011

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Salvatore Perrone, Fulvio Massaro, Giuliana Alimena & Massimo Breccia. (2016) How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety. Expert Opinion on Pharmacotherapy 17:11, pages 1517-1526.
Read now
H. Jean Khoury, Jorge Cortes, Michele Baccarani, Meir Wetzler, Tamas Masszi, Raghunadharao Digumarti, Adam Craig, Annie-Claude Benichou & Luke Akard. (2015) Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. Leukemia & Lymphoma 56:1, pages 120-127.
Read now
Omar Al Ustwani, Elizabeth A Griffiths, Eunice S Wang & Meir Wetzler. (2014) Omacetaxine mepesuccinate in chronic myeloid leukemia. Expert Opinion on Pharmacotherapy 15:16, pages 2397-2405.
Read now
Elias J. Jabbour, Timothy P. Hughes, Jorge E. Cortés, Hagop M. Kantarjian & Andreas Hochhaus. (2014) Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia & Lymphoma 55:7, pages 1451-1462.
Read now

Articles from other publishers (19)

Marie Balsat, Vincent Alcazer, Gabriel Etienne, Françoise Huguet, Marc Berger, Emilie Cayssials, Aude Charbonnier, Martine Escoffre-Barbe, Hyacinthe Johnson-Ansah, Laurence Legros, Lydia Roy, Alain Delmer, Jean-Christophe Ianotto, Corentin Orvain, Fabrice Larosa, Mathieu Meunier, Shanti Amé, Annalisa Andreoli, Pascale Cony-Makhoul, Stéphane Morisset, Isabelle Tigaud, Delphine Rea & Franck Emmanuel Nicolini. (2023) First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia. Leukemia Research 130, pages 107308.
Crossref
Mhairi Copland. (2022) Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity. British Journal of Haematology 199:5, pages 665-678.
Crossref
D. Matmour, N. Si-Ali, N.C. Benmehimda, S. Beloufa, F. Belfrak, E. Mahi, Y. Merad, H. Toumi & M. Benlazar. (2022) Prévalence des Effets Indésirables des Inhibiteurs de Tyrosine Kinase Utilisés dans le Traitement de la Leucémie Myéloïde Chronique au CHU de Sidi Bel-Abbès. Annales Pharmaceutiques Françaises 80:6, pages 932-942.
Crossref
Binoy Yohannan & Binsah George. (2022) B-Lymphoid Blast Phase–Chronic Myeloid Leukemia: Current Therapeutics. International Journal of Molecular Sciences 23:19, pages 11836.
Crossref
You-Wen Tan. (2021) Is dose modification or discontinuation of nilotinib necessary in nilotinib-induced hyperbilirubinemia?. World Journal of Meta-Analysis 9:6, pages 488-495.
Crossref
Joan How, Vinayak Venkataraman & Gabriela Soriano Hobbs. (2021) Blast and accelerated phase CML: room for improvement. Hematology 2021:1, pages 122-128.
Crossref
Massimiliano Bonifacio, Fabio Stagno, Luigi Scaffidi, Mauro Krampera & Francesco Di Raimondo. (2019) Management of Chronic Myeloid Leukemia in Advanced Phase. Frontiers in Oncology 9.
Crossref
Fengling Wang, Jinhui Wang, Zhaozhong Chong & Yanling Mu. (2019) A modified DAW-22 compound F-B1 inhibits Bcr/Abl and induces apoptosis in chronic myelogenous leukemia cells. Anti-Cancer Drugs 30:2, pages 159-166.
Crossref
Ching-Yuan Kuo, Po-Nan Wang, Wen-Li Hwang, Cheng-Hwai Tzeng, Li-Yaun Bai, Jih-Luh Tang, Ming-Chih Chang, Sheng-Fung Lin, Tsai-Yun Chen, Yeu-Chin Chen, Tran-Der Tan, Chih-Yi Hsieh, Chinjune Lin, Clinton Lai, Darko Miljkovic & Cheng-Shyong Chang. (2018) Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study. Therapeutic Advances in Hematology 9:3, pages 65-78.
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 265 281 .
J L Steegmann, M Baccarani, M Breccia, L F Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, T D Kim, H J Khoury, P Le Coutre, J Mayer, D Milojkovic, K Porkka, D Rea, G Rosti, S Saussele, R Hehlmann & R E Clark. (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30:8, pages 1648-1671.
Crossref
Sudipto Mukherjee & Matt Kalaycio. (2016) Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase. Current Hematologic Malignancy Reports 11:2, pages 86-93.
Crossref
Zachariah DeFilipp & Hanna Jean Khoury. (2015) Management of Advanced-Phase Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports 10:2, pages 173-181.
Crossref
H Jiang, L-P Xu, D-H Liu, K-Y Liu, S-S Chen, B Jiang, Q Jiang, H Chen, Y-H Chen, W Han, X-H Zhang, Y Wang, J-Z Wang, F-R Wang, Y-Z Qin, Y-Y Lai & X-J Huang. (2014) Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplantation 49:9, pages 1146-1154.
Crossref
Anna Lau & Mark L Heaney. (2014) Evaluation of response to first-line treatment for chronic myeloid leukemia: has imatinib been outperformed?. International Journal of Hematologic Oncology 3:2, pages 153-168.
Crossref
Elizabeth Irvine & Casey Williams. (2013) Treatment-, Patient-, and Disease-Related Factors and the Emergence of Adverse Events with Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:8, pages 868-881.
Crossref
Pratap Neelakantan & Jane F Apperley. (2013) Nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines. Clinical Practice 10:3, pages 283-291.
Crossref
D J DeAngelo. (2012) Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy. Blood Cancer Journal 2:10, pages e95-e95.
Crossref
G. Etienne. (2012) Traitement par inhibiteurs de tyrosine-kinase de 2e génération chez les patients en échec de l’imatinibTreatment by second-generation tyrosine-kinase inhibitors in patients with imatinib failure. Oncologie 14:10-11, pages 589-595.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.